Article
Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver - 1 Dec 2010
Svicher Valentina, Alteri Claudia, Gori Caterina, Salpini Romina, Marcuccilli Fabbio, Bertoli Ada, Longo Roberta, Bernassola Martina, Gallinaro Valentina, Romano Sara, Visca Michela, Ursitti Antonella, Feasi Marcello, Micheli Valeria, Angelico Mario, Cassola Giovanni, Parruti Giustino, Gubertini Guido, De Sanctis Giuseppe Maria, Ceccherini-Silberstein Francesca, Cappiello Giuseppina, Spanò Alberto, Perno Carlo Federico
Abstract excerpt
OBJECTIVE: To investigate lamivudine (LAM)-resistance profiles of hepatitis B virus (HBV) at the early stages of virological breakthrough (serum HBV-DNA 12-345IU/ml) or when HBV-DNA is undetectable. METHODS: Sixty-four HBV-mono-infected patients were enrolled: 25 had virological breakthrough with serum HBV-DNA ranging from 12 to 345IU/ml during first-line LAM-monotherapy; 24 were on LAM-monotherapy, and 15 were...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.